PT3250554T - Um derivado de carboxamida e os seus diastereómeros na forma cristalina estável - Google Patents

Um derivado de carboxamida e os seus diastereómeros na forma cristalina estável

Info

Publication number
PT3250554T
PT3250554T PT167040294T PT16704029T PT3250554T PT 3250554 T PT3250554 T PT 3250554T PT 167040294 T PT167040294 T PT 167040294T PT 16704029 T PT16704029 T PT 16704029T PT 3250554 T PT3250554 T PT 3250554T
Authority
PT
Portugal
Prior art keywords
diastereomers
carboxamide
derivative
crystalline form
stable crystalline
Prior art date
Application number
PT167040294T
Other languages
English (en)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55349869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3250554(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of PT3250554T publication Critical patent/PT3250554T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT167040294T 2015-01-30 2016-01-28 Um derivado de carboxamida e os seus diastereómeros na forma cristalina estável PT3250554T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20150033 2015-01-30

Publications (1)

Publication Number Publication Date
PT3250554T true PT3250554T (pt) 2022-06-02

Family

ID=55349869

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167040294T PT3250554T (pt) 2015-01-30 2016-01-28 Um derivado de carboxamida e os seus diastereómeros na forma cristalina estável

Country Status (14)

Country Link
US (4) US10010530B2 (pt)
EP (1) EP3250554B1 (pt)
JP (2) JP7283861B2 (pt)
CY (1) CY1125482T1 (pt)
DK (1) DK3250554T3 (pt)
ES (1) ES2917549T3 (pt)
HR (1) HRP20220998T1 (pt)
HU (1) HUE058986T2 (pt)
LT (1) LT3250554T (pt)
PL (1) PL3250554T3 (pt)
PT (1) PT3250554T (pt)
RS (1) RS63477B1 (pt)
SI (1) SI3250554T1 (pt)
WO (1) WO2016120530A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6716023B2 (ja) * 2016-08-26 2020-07-01 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド アンドロゲン受容体拮抗薬の結晶形及びその製造方法並びに用途
CN108218908A (zh) * 2016-12-15 2018-06-29 连云港润众制药有限公司 一种新型雄激素受体拮抗剂的制备方法
CN121181479A (zh) 2017-03-07 2025-12-23 奥赖恩公司 结晶药物产品的制备
CN110944979B (zh) * 2017-08-09 2023-05-12 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
CN107602471B (zh) * 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法
JP2021515040A (ja) * 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
WO2021001603A1 (en) 2019-07-02 2021-01-07 Orion Corporation Pharmaceutical composition of darolutamide
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
CN110452123B (zh) * 2019-08-30 2021-10-29 南京师范大学 一步构建c-c、c-n、c-s键的合成方法
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2022049075A1 (en) 2020-09-02 2022-03-10 Bend Research, Inc. Amorphous solid dispersion of darolutamide
WO2022144926A1 (en) * 2020-12-31 2022-07-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide
EP4486727B1 (en) 2022-02-28 2026-02-25 Química Sintética, S.A. Crystalline form of darolutamide
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
WO2012143599A1 (en) 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides

Also Published As

Publication number Publication date
US20190321333A1 (en) 2019-10-24
US20180008577A1 (en) 2018-01-11
US10376494B2 (en) 2019-08-13
JP2018503662A (ja) 2018-02-08
HUE058986T2 (hu) 2022-09-28
DK3250554T3 (da) 2022-06-27
US10835515B2 (en) 2020-11-17
US20180280354A1 (en) 2018-10-04
US10010530B2 (en) 2018-07-03
CY1125482T1 (el) 2026-02-25
JP7283861B2 (ja) 2023-05-30
US10383853B2 (en) 2019-08-20
SI3250554T1 (sl) 2022-09-30
EP3250554A1 (en) 2017-12-06
WO2016120530A1 (en) 2016-08-04
ES2917549T3 (es) 2022-07-08
PL3250554T3 (pl) 2022-09-19
HRP20220998T1 (hr) 2022-11-11
LT3250554T (lt) 2022-06-10
RS63477B1 (sr) 2022-08-31
EP3250554B1 (en) 2022-05-18
JP2021020935A (ja) 2021-02-18
US20180280355A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
PT3250554T (pt) Um derivado de carboxamida e os seus diastereómeros na forma cristalina estável
IL268852A (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
IL253186B (en) Crystalline form of a benzimidazole derivative and a preparation method thereof
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
EP3355895A4 (en) CRYSTAL FORMS OF BETA NICOTINAMIDE MONONUCLEOTIDE
PT3394259T (pt) Composições e métodos para diminuir a expressão de tau
HUE064559T2 (hu) MAGL inhibitor kristályos formája
HRP20181650T1 (hr) Biciklički heterociklički derivati kao inhibitori bromodomene
HUE040434T2 (hu) Szelektív CDK4/6 inhibitor szilárd alakjai
HUE053112T2 (hu) PDE 4 inhibitor kristályos formája
PL3457851T3 (pl) Pochodne sobetiromu
EP2963036A4 (en) 2-ACYLAMINOTHIAZOL DERIVATIVE AND SALT THEREOF
DK3283210T3 (da) Fremgangsmåde
EP3071554A4 (en) Crystalline forms of lesinurad and its sodium salt
EP3408432A4 (en) PREPARATION OF CRYSTALLINE CELLULOSE
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
IL260004A (en) Crystalline forms of quinolone analogs and their salts
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
HUE043194T2 (hu) PLK-4 inhibitor sója és kristályformái
IL259742A (en) L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
SI3749673T1 (sl) Kristalinična oblika biktegravir natrija
PL3630725T3 (pl) Postać krystaliczna n-butylodeoksygalaktonojirymycyny
LT3327012T (lt) Bilastino kristalinės formos ir jų gamybos būdai
EP3003320A4 (en) NOVEL POLYMORPH OF REGADENOSON
IL253479A0 (en) Crystalline forms of efinconazole